Current Role
  • Partner, Hagens Berman Sobol Shapiro LLP
  • Practice focuses on antitrust, consumer protection and RICO litigation against drug and medical device manufacturers in complex class actions and personal injury cases for consumers, large and small health plans, direct purchasers and state governments
  • Co-lead interim class counsel for end payors in In re Vascepa Antitrust Litigation (D.N.J.)
  • Co-lead class counsel for direct purchasers in In re Intuniv Antitrust Litigation (D. Mass.)
  • As co-lead class counsel, helped secure $453.85 million class settlement for direct purchaser class members shortly before trial in In re Glumetza Antitrust Litigation
  • Serves as counsel to Blue Cross Blue Shield Association in its roles as members of the Unsecured Creditors Committee in the Purdue bankruptcy and the Opioid Creditors Committee in the Mallinckrodt and Endo bankruptcies
  • As co-lead class counsel, helped secure $72.5 million class settlement for direct purchaser class members three days before trial in MDL 2503: In re Solodyn Anitrust Litigation
  • Helped reach a $73 million class settlement for direct purchasers in MDL No. 2343: In re. Skelaxin Antitrust Litigation
  • Represented the state of Connecticut and helped secure a $25M settlement in its’ action against Eli Lilly over unlawful promotion of and misrepresentations about Zyprexa
  • Represented health benefit providers in the firm's Ketek and copay subsidies class litigation, and individuals harmed by pharmaceuticals such as Yaz, Actos and Granuflo and medical devices including pelvic mesh
  • Served as pro bono counsel in a successful constitutional challenge to the Commonwealth of Massachusetts’ exclusion of legal immigrants from the state’s universal healthcare program
  • Served as liaison counsel for In re Fresenius Granuflo/Naturalyte Dialysate Products Liability Litigation
  • Active in the fights against forced arbitration and federal preemption of consumer rights, working to ensure the public maintains access to the civil justice system and the ability to seek remedies when companies violate the law
  • Co-authored an amicus brief to the Supreme Court in Pliva v. Mensing on behalf of practitioners and professors who teach and write on various aspects of pharmaceutical regulation and the delivery of healthcare
  • Worked at Conflict Management Group where she worked with members of the United Nations High Commissioner for Refugees on a pilot project in Bosnia-Herzegovina designed to ease tensions and encourage reconciliation in post-conflict societies, and contributed to Imagine Coexistence, a book developed out of the collaboration
Public Service
  • Serves on the board of On The Rise, a Cambridge, MA daytime shelter for homeless individuals and those in crisis
  • Certificate of Recognition, AAJ, 2022-2023
  • 500 Leading Lawyers in America, Plaintiff Consumer Lawyers, Lawdragon, 2019-present
  • 500 Leading Lawyers in America, Plaintiff Financial Lawyers, Lawdragon, 2019-present
  • Massachusetts Super Lawyer, 2018-2023
  • Distinguished Service Award, American Association for Justice, 2015, 2017, 2018, 2021
  • Women’s Caucus Excellence in Leadership Award, American Association for Justice, 2017, 2019
  • Marie Lambert Award, American Association for Justice, 2018
  • Emerging Leaders Board of Advisors, inaugural class, Institute for Complex Litigation and Mass Claims at Emory Law, 2015-2017
  • Above and Beyond Award, American Association for Justice, 2016
  • Massachusetts Rising Star, Super Lawyers, 2014-2015
  • Boston Rising Star Award, The National Law Journal, 2014
  • President’s Award, Massachusetts Academy of Trial Attorneys, 2014
  • New Lawyers Division Excellence Award, American Association for Justice, 2010, 2011, 2013, 2014
  • Up & Coming Lawyer Award, Massachusetts Bar Association, 2013
  • Wiedemann & Wysocki Award, American Association for Justice, 2012, 2013
  • New Lawyers Division Above and Beyond Award, American Association for Justice, 2012
Notable Cases
  • $453.85 Million Recovery in Glumetza Antitrust Action
    In February 2022, the Honorable William Alsup of the Northern District of California granted final approval to a $453.85 million class settlement for direct purchasers of brand and generic Glumetza. HBSS was co-lead class counsel in this case alleging Bausch, through its predecessors, and Assertio entered into a reverse payment agreement with Lupin to delay entry of generic Glumetza and, in the intervening period of delay, hiked the price of this diabetes drug grotesquely, all resulting in substantial overcharges by direct purchasers. The case settled shortly before trial. In re Glumetza Antitrust Litigation, N.D. Ca., [3:19-cv-05822-WHA]
  • $72.5 Million Recovery in Solodyn Antitrust Action
    In July 2018, the Honorable Denise J. Casper of the District of Massachusetts granted final approval to a $72.5 million class settlement for direct purchasers of brand and generic Solodyn. HBSS was co-lead class counsel in this case alleging Medicis entered into a series of reverse payment deals to delay entry of generic Solodyn and used the period of delay to effectuate a product hop, all resulting in overcharges by direct purchasers. The case settled three days before trial.
    In re Solodyn Antitrust Litigation, D. Mass., MDL No. 2503
  • $73 Million Recovery for Direct Purchasers of Skelaxin
    On Sept. 24, 2014, Judge Curtis Collier of the Eastern District of Tennessee approved a $73 million settlement for direct purchasers of Skelaxin in litigation alleging Skelaxin’s manufacturer colluded with would-be generic competitors, fraudulently delaying generic competition and leading to higher prices. Metaxalone was sold under the brand name Skelaxin since 1962, but the original patent expired in 1979. Manufacturers applied to market generic metaxalone in 2002, and generic competitors remained foreclosed from marketing generic metaxalone until 2010. Hagens Berman served as lead counsel for direct purchasers.
    In re Skelaxin (Metaxalone) Antitrust Litigation, E.D.TN., Civil Action No. 1:12-md-2343.
  • Health care coverage for 40,000 legal immigrants in Massachusetts
    On Jan. 5, 2012, the Massachusetts Supreme Judicial Court ruled unanimously that a state law barring 40,000 low-income legal immigrants from the state’s universal health care program unconstitutionally violates those immigrants’ rights to equal protection under the law and must be struck down. Hagens Berman served as pro bono counsel.
    Finch v. Commonwealth Health Insurance Connector Authority, Mass., Civil Action No. SJC-11025.
  • $25 million for the state of Connecticut for Zyprexa fraud
    On Oct. 5, 2009, U.S. District Court Judge Jack B. Weinstein approved a $25 million settlement reached by the parties to conclude the state’s Zyprexa litigation that alleged Lilly engaged in unlawful off-label promotion and misrepresented Zyprexa’s safety and efficacy, resulting in millions of dollars in excess pharmaceutical costs. Hagens Berman served as outside counsel to Attorney General Richard Blumenthal.
    State of Connecticut v. Eli Lilly & Co., E.D.N.Y., Civil Action No. 08-cv-955-JBW.
Personal Insight

Unlike many of her colleagues at HBSS, Lauren does not run marathons – unless chasing after her three children counts. Lauren did wrestle in college but refused to don the wrestling singlet. Whenever she can, Lauren rock climbs with her in-laws, breathes deeply at yoga, and hosts dinner parties to, despite usual advice, try totally new recipes. She also keeps the pizza delivery guy on speed dial as back-up for such occasions.